Kathryn Ruddy

Professor

Mayo Clinic
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

About

Professor Kathryn Ruddy is a faculty member at Mayo Clinic in the United States. Her research primarily focuses on the quality of life and oncologic outcomes in women with hormone receptor-positive breast cancer. She has published recent studies comparing the efficacy of bilateral oophorectomy and gonadotropin-releasing hormone agonist therapy.

Articles (10)

Year:

2026

Background: Mu opioid receptors (MORs) in peripheral tissues mediate adverse effects of opioids that impair health-related quality of life (HRQoL) and may stimulate cancer progression via mitogenic signaling. Naloxegol, a peripherally acting MOR antagonist (PAMORA), is approved for opioid-induced constipation. Safety and efficacy of naloxegol have not been evaluated concurrently with systemic cancer therapy. Methods: We conducted a randomized, double-blind, placebo-controlled trial of naloxegol in patients with advanced lung adenocarcinoma starting first-line systemic therapy. Results: Only 50 patients were enrolled; the trial was terminated early due to slow accrual. Two of the three components of the feasibility primary endpoint were not met (accrual and PRO completion). At 6 months, FACT-L emotional well-being was better with naloxegol (p = 0.0113). There were trends towards better Trial Outcome Index (p = 0.0505) and physical well-being (p = 0.0628) with naloxegol. Bowel function favored naloxegol for constipation (p = 0.0223), rectal pain during defecation (p = 0.0075), and abdominal pain from constipation (p = 0.0113). Adverse event frequency and severity, PRO-CTCAE, urinary hesitancy, pain scores, and progression-free and overall survival were comparable between naloxegol and placebo. Conclusions: Naloxegol appears to be safe and tolerable, with a signal of improved HRQoL and previously unappreciated benefit for emotional well-being, without adverse clinical outcomes. Our findings should be confirmed in larger studies. ClinicalTrials.gov ID: NCT03087708.

Year:

2026

Background/Objectives: This study aims to evaluate the quality of life (QoL) and oncological outcomes in premenopausal women diagnosed with hormone receptor-positive breast cancer who are receiving either bilateral oophorectomy (BO) or gonadotropin-releasing hormone agonist (GnRH) therapy. Both methods serve to inhibit ovarian function, which is essential for the management of estrogen-dependent tumors; however, their effects on QoL have yet to be fully clarified. Methods: Data were analyzed from the Mayo Clinic Breast Disease Registry, focusing on women under 55 diagnosed with estrogen receptor-positive breast cancer who received either BO or GnRH within one year of diagnosis. QoL was assessed using the Patient-Reported Outcomes Measurement Information System Global-10 (PROMIS-10) at baseline and annually for five years. Results: A total of 181 patients were enrolled in the study; 40 into the BO group and 141 to the GnRH group. Both groups exhibited similar levels of sexual dysfunction after a one-year period; however, the BO group stated a higher frequency of hot flashes. PROMIS-10 scores improved in both mental and physical health over time, with no significant differences between the groups. Within the BO group, one recurrence was observed, in contrast to the GnRH group, which had six events. Nonetheless, the difference in recurrence rates did not reach statistical significance. Conclusions: The long-term QoL and oncologic outcomes for premenopausal women with hormone receptor-positive breast cancer were similar for BO and GnRH therapy. These findings emphasize the need for individualized treatment decisions, considering patient preferences and side effects.

Year:

2025

Treatment-induced ovarian function loss is a significant concern for many young patients with breast cancer. Accurately predicting this risk is crucial for counselling young patients and informing their fertility-related decision-making. However, current risk prediction models for treatment-related ovarian function loss have limitations. To provide a broader representation of patient cohorts and improve feature selection, we combined retrospective data from six datasets within the FoRECAsT (Infertility after Cancer Predictor) databank, including 2679 pre-menopausal women diagnosed with breast cancer. This combined dataset presented notable missingness, prompting us to employ cross imputation using the k-nearest neighbours (KNN) machine learning (ML) algorithm. Employing Lasso regression, we developed an ML model to forecast the risk of treatment-related amenorrhea as a surrogate marker of ovarian function loss at 12 months after starting chemotherapy. Our model identified 20 variables significantly associated with risk of developing amenorrhea. Internal validation resulted in an area under the receiver operating characteristic curve (AUC) of 0.820 (95% CI: 0.817–0.823), while external validation with another dataset demonstrated an AUC of 0.743 (95% CI: 0.666–0.818). A cutoff of 0.20 was chosen to achieve higher sensitivity in validation, as false negatives—patients incorrectly classified as likely to regain menses—could miss timely opportunities for fertility preservation if desired. At this threshold, internal validation yielded sensitivity and precision rates of 91.3% and 61.7%, respectively, while external validation showed 92.9% and 60.0%. Leveraging ML methodologies, we not only devised a model for personalised risk prediction of amenorrhea, demonstrating substantial enhancements over existing models but also showcased a robust framework for maximally harnessing available data sources.

Year:

2025

Frequencies of all reported germline CHEK2 variant carriers and carriers of variants concordantly categorized by functional our kinase assays in breast cancer patients and controls in 12 analyzed population datasets.

Year:

2025

Background Breast cancer (BC) survivors frequently experience sleep disturbances, which may persist for many years after treatment. This study aimed to describe trends in sleep-related symptoms over time and identify factors that may be associated with sleep disturbances in BC survivors. Patients and Methods Adult patients from the Mayo Clinic Breast Disease Registry were surveyed annually for up to 7 years post-diagnosis. Sleep disturbance severity was assessed using numeric rating scales for difficulty falling and staying asleep. Data from 3354 unique patients were analyzed, excluding those with metastatic disease or recurrence. Univariable and multivariable analyses were performed at the 1-year survey timepoint to evaluate disease and patient-related factors that were associated with increased sleep-related symptoms, and these factors were also assessed in relationship to sleep-related symptoms over time. Results In multivariable analyses, more trouble falling asleep was associated with financial insecurity, higher clinical stage, more cigarettes smoked per day, and less weekly exercise. More trouble staying asleep was associated with older age, race, advanced education, financial insecurity, and higher clinical stage. Over time, there was a nonsignificant trend toward increased trouble falling asleep and fluctuations in trouble staying asleep. Higher clinical stage and receipt of radiotherapy were associated with decreased severity in trouble falling asleep over time, while more cigarettes smoked per day was linked to increased severity in trouble staying asleep. Conclusions These findings highlight the complex interplay of clinical, lifestyle, and demographic factors in sleep disturbances among BC survivors, underscoring the need for tailored sleep management strategies.

Year:

2025

Purpose: To determine the relationship between germline pathogenic variants (PV) in cancer predisposition genes and the risk of ductal carcinoma in situ (DCIS). Experimental Design: Germline PV frequencies in breast cancer predisposition genes ( ATM , BARD1 , BRCA1 , BRCA2 , CDH1 , CHEK2 , PALB2 , RAD51C , and RAD51D ) were compared between DCIS cases and unaffected controls and between DCIS and invasive ductal breast cancer (IDC) cases from a clinical testing cohort ( n = 9,887), a population-based cohort ( n = 3,876), and the UK Biobank ( n = 2,421). The risk of contralateral breast cancer (CBC) for DCIS cases with PV was estimated in the population-based cohort. Results: Germline PV were observed in 6.5% and 4.6% of women with DCIS in the clinical testing and population-based cohorts, respectively. BRCA1 , BRCA2 , and PALB2 PV frequencies were significantly lower among women with DCIS than those with IDC (clinical cohort: 2.8% vs. 5.7%; population-based cohort: 1.7% vs. 3.7%), whereas the PV frequencies for ATM and CHEK2 were similar. ATM , BRCA1 , BRCA2 , CHEK2 , and PALB2 PV were significantly associated with an increased risk of DCIS (OR > 2.0), but only BRCA2 PV were associated with high risk (OR > 4) in both cohorts. The cumulative incidence of CBC among carriers of PV in high-penetrance genes with DCIS was 23% over 15 years. Conclusions: The enrichment of PV in ATM , BRCA1 , BRCA2 , CHEK2 , and PALB2 among women with DCIS suggests that multigene panel testing may be appropriate for women with DCIS. Elevated risks of CBC in carriers of PV in high-penetrance genes with DCIS confirmed the utility of testing for surgical decision-making.

Year:

2025

Background Following breast cancer (BC), many young women are interested in future childbearing and some may wish to breastfeed. However, limited information is available regarding their lactation experiences. Methods Participants in the Young Women's Breast Cancer Study, a multicenter, prospective cohort study of women ≤40 years diagnosed with stage 0–III BC between 2006–2016 and who reported one or more live births following diagnosis, were surveyed about pregnancy and breastfeeding after BC treatment, including reasons for attempting and stopping breastfeeding, satisfaction, and supports. Results Of 143 eligible women sent a survey, 115 responded and 94 were included in the analytic cohort. Breastfeeding was attempted by 55% of women (52 of 94). Among those who had not attempted, 93% noted prior bilateral mastectomies (39 of 42). Among those who attempted breastfeeding, 69% had undergone lumpectomy and radiotherapy (36 of 52), 83% of whom reported no milk production from their treated breast (30 of 36). Most (65%, 34 of 52) were at least somewhat satisfied with their ability to breastfeed. Reasons for stopping breastfeeding included: having completed the planned duration (36%, 19 of 52); to start/resume endocrine therapy (21%, 11 of 52); and to resume breast imaging (8%, 4 of 52). Approximately half (27 of 55) of women who had not undergone bilateral mastectomies recalled receiving specific information about breastfeeding after BC, mostly from the oncology team (59%, 16 of 27), online resources (48%, 13 of 27), or a lactation consultant (44%, 12 of 27). Conclusion Most young BC survivors who attempted to breastfeed were able to and were satisfied with the experience, despite challenges. Specific resources to support BC survivors who wish to breastfeed are needed.

Year:

2024

Purpose: We previously reported that postmenopausal women with estrogen receptor-α–positive breast cancer receiving adjuvant anastrozole 1 mg/day (ANA1) with estrone (E1) ≥1.3 pg/mL and estradiol (E2) ≥0.5 pg/mL [inadequate estrogen suppression (IES)] had a threefold increased risk of a breast cancer event. The objective of this study was to determine if increasing anastrozole to 10 mg/day (ANA10) could result in adequate estrogen suppression (AES: E1 Patients and Methods: Postmenopausal women with estrogen receptor-α–positive breast cancer planning to receive adjuvant ANA1 were eligible. E1 and E2 were assessed pre- and post-8 to 10 weeks of ANA1. Those with IES were switched to 8- to 10-week cycles of ANA10 followed by letrozole 2.5 mg/day. E1 and E2 were assessed after each cycle. Anastrozole concentrations were measured post-ANA1 and post-ANA10. Primary analyses included patients who documented taking at least 80% of the planned treatment (adherent cohort). Results: In total, 132 (84.6%) of 156 eligible patients were ANA1 adherent. IES occurred in 40 (30.3%) adherent patients. Twenty-five (78.1%) of 32 patients who began ANA10 were adherent, and AES was achieved in 19 (76.0%; 90% confidence interval, 58.1%–89.0%) patients. Anastrozole concentrations post-ANA1 and post-ANA10 did not differ by estrogen suppression status among adherent patients. AES was maintained/attained in 21 (91.3%) of 23 letrozole-adherent patients. Conclusions: Approximately 30% of ANA1-adherent patients had IES. Among those who switched to ANA10 and were adherent, 76% had AES. Further studies are required to validate emerging data that ANA1 results in IES for some patients and to determine the clinical benefit of switching to ANA10 or an alternative aromatase inhibitor.

Year:

2024

Purpose: We previously reported that postmenopausal women with estrogen receptor-α–positive breast cancer receiving adjuvant anastrozole 1 mg/day (ANA1) with estrone (E1) ≥1.3 pg/mL and estradiol (E2) ≥0.5 pg/mL [inadequate estrogen suppression (IES)] had a threefold increased risk of a breast cancer event. The objective of this study was to determine if increasing anastrozole to 10 mg/day (ANA10) could result in adequate estrogen suppression (AES: E1 Patients and Methods: Postmenopausal women with estrogen receptor-α–positive breast cancer planning to receive adjuvant ANA1 were eligible. E1 and E2 were assessed pre- and post-8 to 10 weeks of ANA1. Those with IES were switched to 8- to 10-week cycles of ANA10 followed by letrozole 2.5 mg/day. E1 and E2 were assessed after each cycle. Anastrozole concentrations were measured post-ANA1 and post-ANA10. Primary analyses included patients who documented taking at least 80% of the planned treatment (adherent cohort). Results: In total, 132 (84.6%) of 156 eligible patients were ANA1 adherent. IES occurred in 40 (30.3%) adherent patients. Twenty-five (78.1%) of 32 patients who began ANA10 were adherent, and AES was achieved in 19 (76.0%; 90% confidence interval, 58.1%–89.0%) patients. Anastrozole concentrations post-ANA1 and post-ANA10 did not differ by estrogen suppression status among adherent patients. AES was maintained/attained in 21 (91.3%) of 23 letrozole-adherent patients. Conclusions: Approximately 30% of ANA1-adherent patients had IES. Among those who switched to ANA10 and were adherent, 76% had AES. Further studies are required to validate emerging data that ANA1 results in IES for some patients and to determine the clinical benefit of switching to ANA10 or an alternative aromatase inhibitor.

Year:

2024

Collaborators (74)

Tomáš Zima

Head of Institute

Charles University and General University Hospital in Prague, First Faculty of Medicine

CZECH REPUBLIC
View details

Kathleen Claes

Full professor

Ghent University Hospital

BELGIUM
View details

Giuseppe Matullo

-

ITALY
View details

Lisa Wiesmüller

Professor

Ulm University

GERMANY
View details

Christopher A. Haiman

University of Southern California

UNITED STATES
View details

Hadi Akbarzadeh Khorshidi

Senior Research Fellow

MONASH UNIVERSITY

AUSTRALIA
View details

Christine Ambrosone

Roswell Park Comprehensive Cancer Center

UNITED STATES
View details

Eric Hahnen

-

GERMANY
View details

Susan Domchek

Professor, Clinician-Educator

University of Pennsylvania

UNITED STATES
View details

Sara Lindström

University of Washington

UNITED STATES
View details

Maria Rossing

Associate Clinical Professor

Copenhagen University Hospital

DENMARK
View details

Marco Montagna

Istituto Oncologico Veneto

ITALY
View details

Katherine Nathanson

Professor

University of Pennsylvania

UNITED STATES
View details

Nicoletta Resta

Full Professor Medical Genetics

University of Bari Aldo Moro

ITALY
View details

Song Yao

Professor

Roswell Park Comprehensive Cancer Center

UNITED STATES
View details

Maria Piane

Sapienza University of Rome

ITALY
View details

Sara González

Institut Català d'Oncologia

SPAIN
View details

FEI CHEN

Assistant Professor

University of Southern California

UNITED STATES
View details

Katie O'Brien

Staff Scientist

National Institute of Environmental Health Sciences

UNITED STATES
View details

A Heather Eliassen

Professor

Harvard University

UNITED STATES
View details

Alexandra Martins

INSERM

FRANCE
View details

Dale Sandler

Branch Chief

National Institute of Environmental Health Sciences

UNITED STATES
View details

Julie R Palmer

Boston University School of Medicine

UNITED STATES
View details

Clarice Weinberg

Principal Investigator

National Institute of Environmental Health Sciences

UNITED STATES
View details

Alexander E Volk

-

GERMANY
View details

Lidia Schapira

Professor of Medicine

Stanford University

UNITED STATES
View details

Peter Kraft

Professor

Harvard T.H. Chan School of Public Health

UNITED STATES
View details

Zeruesenay Desta

Professor of Medicine

Indiana University

UNITED STATES
View details

Siddhartha Yadav

Associate Professor of Oncology

Mayo Clinic

UNITED STATES
View details

Mariarosaria Calvello

European Institute of Oncology

ITALY
View details

anna coppa

Sapienza University of Rome

ITALY
View details

Allison DePersia

NorthShore University HealthSystem

UNITED STATES
View details

Charles Loprinzi

Regis Professor of Breast Cancer Oncology

Mayo Clinic

UNITED STATES
View details

Paul James

Head of Adult Genetics

The Royal Melbourne Hospital Royal Park Campus

AUSTRALIA
View details

Florentia Fostira

National Centre for Scientific Research-Demokritos

GREECE
View details

Paolo Radice

Head of Reserach Unit

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY
View details

Maria Elena. Martinez

University of California

UNITED STATES
View details

Marketa Janatova

Assistanf Professor and researcher

Přírodovědecká Fakulta, Univerzita Karlova

CZECH REPUBLIC
View details

Matthew Goetz

Professor of Oncology and Pharmacology

Mayo Clinic

UNITED STATES
View details

Karthik Giridhar

Assistant Professor

Mayo Clinic

UNITED STATES
View details

Gareth Evans

The University of Manchester

UNITED KINGDOM
View details

Esther John

Professor

Stanford University School of Medicine

UNITED STATES
View details

Weng Khong Lim

Assistant Professor

Duke-NUS Medical School

SINGAPORE
View details

Barbara Pasini

Associate Professor of Medical Genetics

Università degli Studi di Torino

ITALY
View details

Ian Campbell

Group Leader

Peter MacCallum Cancer Institute

AUSTRALIA
View details

Robert A. Kratzke

University of Minnesota

UNITED STATES
View details

Stacey J. Winham

Mayo Clinic College of Medicine and Science

UNITED STATES
View details

Matteo Lambertini

University of Genova

ITALY
View details

Ravinder Singh

Professor

Mayo Clinic

UNITED STATES
View details

Jeffrey Weitzel

Professor and Director

University of Kansas Cancer Center

UNITED STATES
View details

H. Irene Su

University of California, San Diego

UNITED STATES
View details

Lyudmila Bazhenova

University of California

UNITED STATES
View details

Banu K. Arun

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Ellen Warner

University of Toronto

CANADA
View details

Paul Auer

Professor

Medical College of Wisconsin

UNITED STATES
View details

Hoda Anton-Culver

Professor and Chair

University of California, Irvine

UNITED STATES
View details

James Ingle

Mayo Clinic Rochester

UNITED STATES
View details

Ellen Smith

The University of Alabama

UNITED STATES
View details

Alvaro Monteiro

Senior Member - Full Professor

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Corinna Ernst

Hannover Medical School

GERMANY
View details

Saranya Chumsri

Professor of Oncology

Mayo Clinic Florida

UNITED STATES
View details

Lidia Feliubadaló

Institut Català d'Oncologia

SPAIN
View details

Koichi Matsuda

University of Tokyo

JAPAN
View details

Kimberly A. Bertrand

Associate Professor of Medicine

Boston University

UNITED STATES
View details

Joanne Ngeow

Head

Nanyang Technological University (NTU)

SINGAPORE
View details

Anne-Sophie HAMY

Institut Curie

FRANCE
View details

Eric Polley

Associate Professor

University of Chicago

UNITED STATES
View details

Zdenek Kleibl

Laboratory of oncogenetics (head)

Charles University, First Faculty of Medicine

CZECH REPUBLIC
View details

Ann Partridge

Vice Chair

Dana-Farber Cancer Institute

UNITED STATES
View details

Kostandinos Sideras

Assistant Professor

Mayo Clinic

UNITED STATES
View details

Nicholas Boddicker

Research Associate

Mayo Clinic

UNITED STATES
View details

Amanda Toland

Ohio State University

UNITED STATES
View details

Argyrios Ziogas

Professor

University of California, Irvine

UNITED STATES
View details

Laura Cortesi

University of Modena and Reggio Emilia

ITALY
View details